OnKure Therapeutics, Inc.

OKURSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1637715

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	—	$0.00	—	—	—
Research and Development Expense	$43.8M	$32.1M	$37.7M	$28.2M	$15.9M
Operating Expenses	$54.4M	$36.9M	$53.8M	$39.8M	$19.6M
Operating Income (Loss)	-$54.4M	-$36.9M	-$53.8M	-$39.8M	-$19.6M
Other Nonoperating Income (Expense)	—	—	$1.9M	$48.0K	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	-$52.0M	-$39.8M	-$19.5M
Income Tax Expense (Benefit)	$0.00	—	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$52.7M	-$35.3M	-$52.0M	-$39.8M	-$19.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$114.9M	$35.7M	$108.2M	$154.0M	$55.2M
Assets, Current	$113.0M	$33.8M	$106.4M	$153.7M	$55.0M
Cash and Cash Equivalents, at Carrying Value	$110.8M	$29.9M	$19.9M	$124.7M	$53.6M
Liabilities	$11.1M	$7.8M	$8.2M	$6.8M	$4.6M
Liabilities, Current	$10.5M	$7.3M	$7.1M	$6.2M	$4.6M
Accounts Payable, Current	$3.0M	$3.4M	$1.9M	$2.0M	$908.0K
Stockholders' Equity Attributable to Parent	-$101.8M	-$54.4M	$147.2M	-$42.1M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$51.1M	-$34.5M	-$47.4M	-$38.0M	-$18.5M
Net Cash Provided by (Used in) Investing Activities	$15.9M	-$246.0K	-$57.8M	-$23.4M	$7.4M
Net Cash Provided by (Used in) Financing Activities	$116.1M	$53.1M	$471.0K	$132.4M	$47.3M
Payments to Acquire Property, Plant, and Equipment	$52.0K	$246.0K	$346.0K	$198.0K	$24.0K
Payments for Repurchase of Common Stock	—	—	$4.4M	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)